111 related articles for article (PubMed ID: 28739731)
1. Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.
Zhao Q; Kun D; Hong B; Deng X; Guo S; Tang X; Yang Y; Gong K; Li Q; Ye L; Jiang WG; Zhang N
Anticancer Res; 2017 Aug; 37(8):4379-4388. PubMed ID: 28739731
[TBL] [Abstract][Full Text] [Related]
2. The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma.
Zhang N; Wu P; Wu L; Shayiremu D; Shan H; Ye L; Jiang WG; Gong K; Yang Y
Cancer Genomics Proteomics; 2013; 10(1):47-53. PubMed ID: 23382586
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth inhibitor 174 and its functional domains inhibit epithelial-mesenchymal transition in renal cell carcinoma cells in vitro.
Zhang N; Hong B; Lian W; Zhou C; Chen S; Du X; Deng X; Duoerkun S; Li Q; Yang Y; Gong K
Int J Mol Med; 2017 Aug; 40(2):569-575. PubMed ID: 28656288
[TBL] [Abstract][Full Text] [Related]
4. Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial-Mesenchymal Transition in Renal Cell Carcinoma
Zhao Q; Deng X; Hong B; Wang F; Tang X; Yang Y; Gong K; Ye L; Jiang WG; Zhang N
Anticancer Res; 2017 Aug; 37(8):4269-4275. PubMed ID: 28739718
[TBL] [Abstract][Full Text] [Related]
5. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
[TBL] [Abstract][Full Text] [Related]
6. VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma.
Zhao Q; Hong B; Liu T; Ji Y; Tang X; Gong K; Ye L; Yang Y; Zhang N
Int J Oncol; 2019 Jan; 54(1):390-398. PubMed ID: 30431089
[TBL] [Abstract][Full Text] [Related]
7. Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma.
Zhao Q; Liu T; Hong B; Wang F; Zhou C; Du X; Chen S; Deng X; Duoerkun S; Li Q; Yang Y; Gong K; Zhang N
Appl Immunohistochem Mol Morphol; 2018; 26(10):727-733. PubMed ID: 28362712
[TBL] [Abstract][Full Text] [Related]
8. [Expression and role of vascular endothelial growth inhibitor in sporadic clear cell renal cell carcinoma].
Wu LY; Cheng H; Deng XH; Shan H; Wang W; Yang Y; Zhang XD; Zhang N
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):741-5. PubMed ID: 23755810
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma.
Wu L; Li X; Ye L; Shayiremu D; Deng X; Zhang X; Jiang W; Yang Y; Gong K; Zhang N
Anticancer Res; 2014 Feb; 34(2):715-22. PubMed ID: 24511004
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.
Mizutani Y; Nakanishi H; Yamamoto K; Li YN; Matsubara H; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
J Clin Oncol; 2005 Jan; 23(3):448-54. PubMed ID: 15572731
[TBL] [Abstract][Full Text] [Related]
11. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
[TBL] [Abstract][Full Text] [Related]
12. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Wakita T; Hayashi T; Nishioka J; Tamaru H; Akita N; Asanuma K; Kamada H; Gabazza EC; Ido M; Kawamura J; Suzuki K
Int J Cancer; 2004 Feb; 108(4):516-23. PubMed ID: 14696115
[TBL] [Abstract][Full Text] [Related]
13. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
14. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells.
Ren J; Li W; Liu H; Yan L; Jiao W; Li D; Tang Y; Gu G; Xu Z
Urol Oncol; 2013 Oct; 31(7):1358-66. PubMed ID: 22341977
[TBL] [Abstract][Full Text] [Related]
17. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
19. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
